Stealth’s Elamipretide Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By Sue Sutter
  
Climbing steep hill
Stealth faces a steep hill at the FDA cardio-renal adcomm on elamipretide. • Source: Shutterstock

More from US FDA Performance Tracker

More from US Advisory Committees